Cambrex Corporation

One Meadowlands Plaza
07073 East Rutherford
US

Contact WebSite

Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services.

With over 40 years of experience and a team of 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid-state science, material characterization, and highly potent APIs.

Article

17.10.2024 • News

Cambrex Opens New Stability Storage Facility

Today, Cambrex announced its stability storage business, Q1 Scientific, and opened a new cGMP facility in Durham, North Carolina, expanding its capacity for environmentally controlled stability storage services to North America's pharmaceutical, medical device, and life sciences industries.

26.09.2024 • News

Cambrex Announces New Peptide Synthesis Manufacturing Technology

Cambrex announced that Snapdragon Chemistry, a Cambrex company, has developed a new liquid-phase peptide synthesis (LPPS) technology utilizing active pharmaceutical ingredient (API) batch reactors and continuous flow.

20.09.2024 • Topics • Chemistry

Expert Statement: Frank Ferrante, Cambrex

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

06.11.2023 • News

Noramco Acquires Drug Product Business Unit from Cambrex

Noramco, a US producer of active pharmaceutical ingredients (APIs), has completed the acquisition of the Cambrex drug product business unit previously known as Halo Pharmaceuticals. Financial details were not disclosed.

23.11.2022 • News

Cambrex Takes Snapdragon Chemistry

US CDMO Cambrex has agreed to buy Snapdragon Chemistry, a compatriot company specializing in developing continuous flow and batch processes for APIs. Snapdragon is based in Waltham, Massachusetts, where it employs 74 people.

04.11.2022 • News

Cambrex Invests in US R&D Facility

Cambrex is investing in a new R&D facility in Minneapolis, Minnesota, USA, expanding its capacity for small molecule development and manufacturing.

08.06.2021 • News

Cambrex Upgrades Estonia Facility

US CDMO Cambrex has upgraded its facility in Tallin, Estonia. The installation of a new 160-liter reactor train at the kilogram-scale laboratory has expanded Cambrex’s capabilities to manufacture material for clinical trials and allow early-phase projects to be developed further prior to technical transfer and scale-up.

16.07.2020 • News

Cambrex Expands Swedish Drugs Facility

Cambrex is spending $3.6 million to expand flexible drug substance manufacturing at its site in Karlskoga, Sweden. Engineering has already begun, and work is expected to be completed by November 2020.

20.04.2020 • Topics • Chemistry

Experts Statements: Shawn Conway, Cambrex High Point

The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.